Indatuximab ravtansine

Indatuximab ravtansine
Monoclonal antibody
Type Whole antibody
Source Chimeric (mouse/human)
Target SDC1
Identifiers
CAS Number 1238517-16-2 N
ATC code None
ChemSpider none
 NYesY (what is this?)  (verify)

Indatuximab ravtansine (BT062) is an immunomodulator and antineoplastic antibody-drug conjugate.

It is the anti-CD138 chimerized MAb (nBT062)[1] linked to the maytansinoid DM4.[1]

It is being investigated as part of a treatment for multiple myeloma.[1]

Clinical trials

Multiple Myeloma

Preliminary data has been reported in 2013 from an early stage clinical trial in combination with Lenalidomide and Dexamethasone.[1] Follow up data reported "encouraging efficacy" in Dec 2014.[2]

Other

As of December 2014 it is in clinical trials for triple negative metastatic breast cancer and metastatic urinary bladder cancer.[2]

Mechanism of action

CD138 (Syndecan-1) is highly overexpressed on various solid tumors and in hematological malignancies, and represents one of the most specific target antigens for identification of multiple myeloma (MM) cells.[1] The antibody part binds to CD138 on the target cells and then the DM4 kills the cell.

See also

References

  1. 1 2 3 4 5 Indatuximab Ravtansine (BT062) In Combination With Lenalidomide and Low-Dose Dexamethasone In Patients With Relapsed and/Or Refractory Multiple Myeloma: Clinical Activity In Len/Dex-Refractory Patients
  2. 1 2 Biotest AG: Encouraging Efficacy of Indatuximab Ravtansine (BT-062) in Multiple Myeloma in combination with Lenalidomide and Dexamethasone


This article is issued from Wikipedia - version of the Tuesday, February 02, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.